February 5, 2024
More than 700 nuclear medicine physicians, pharmacists, scientists, technologists, laboratory professionals, and industry partners from around the world gathered in Orlando, Florida, on February 1-3 for the SNMMI Mid-Winter and ACNM Annual Meeting. The meeting offered attendees the chance to learn from experts in the field and enhance their skills in order to provide the best possible care for patients.
This year’s meeting included three distinct educational tracks: an ACNM Annual Meeting track focused on molecular imaging, a radiopharmaceutical therapy specialty track covering various therapies as well as operationalizing a therapy center, and a general nuclear medicine track with sessions on diagnostic imaging innovations, clinical trials, dosimetry and more.
Of particular interest were sessions on clinical implementation of cutting-edge therapy research, such as alpha therapy, peptide receptor radionuclide therapy, prostate cancer therapy, new targets and combination therapy. Also popular were sessions on pediatric therapy, the role of artificial intelligence in revolutionizing nuclear medicine, and setting up a theranostics center. Six satellite symposia were offered on topics including brain and prostate cancer imaging and insights into the new era of molecular imaging.
The ACNM Annual Meeting provided an opportunity for attendees to present new research; 107 abstracts were accepted, 20 as oral presentations and 87 as posters. The College also presented its annual awards, including the ACNM Gold Medal to Richard Wahl, MD; Lifetime Achievement, Michael Knopp, MD, PhD; Best Personal Mentor, David Mankoff, MD, PhD; Best Clinical Mentor, Erica Cohen Major, DO, MPH; and Mandell-Alavi Lectureship, Lisa Bodei, MD, PhD. A full list is available on the ACNM website.
More than 40 nuclear medicine and molecular imaging companies were represented in the sold-out exhibit hall, offering attendees the chance to converse directly with industry professionals and explore the latest technologies and products available in the field.
“The expertise and breadth of information included in this meeting attracted attendees from around the world, and the intimate setting was ideal for networking with peers,” said Heather Jacene, MD, chair of the SNMMI Scientific Program Committee. “By all accounts this year’s meeting was a success, and we look forward to meeting with our colleagues again at the SNMMI Annual Meeting in June.”
The 2024 SNMMI Annual Meeting will be held June 8-11, in Toronto, Ontario, Canada. For more information on the meeting, please visit www.snmmi.org/am.
About the Society of Nuclear Medicine and Molecular Imaging
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) is an international scientific and medical organization dedicated to advancing nuclear medicine and molecular imaging—vital elements of precision medicine that allow diagnosis and treatment to be tailored to individual patients in order to achieve the best possible outcomes.
SNMMI’s members set the standard for molecular imaging and nuclear medicine practice by creating guidelines, sharing information through journals and meetings and leading advocacy on key issues that affect molecular imaging and therapy research and practice. For more information, visit www.snmmi.org.